恩度联合化疗治疗晚期恶性肿瘤的临床观察

Rh-endostatin Injection Combined with Chemotherapy on Advanced Malignancies

目的观察恩度(重组人血管内皮抑制素)联合化疗治疗多种晚期恶性肿瘤的有效性和安全性。方法经病理组织学或细胞学检查确诊的IV期恶性肿瘤患者18例,,其中非小细胞肺癌10例,胃肠肿瘤6例,其他肿瘤2例。患者接受恩度联合化疗的方案治疗,同时联合既往未使用的或与既往治疗无交叉耐药的化疗药物。21天为1个周期。用药1周期即可评价毒性,2周期后评价疗效。结果全组18例,获CR0例,PR10例,SD4例,PD4例,即客观有效率(RR)为55.6%(10/18),疾病控制率(DCR)为77.78%(14/18)。结论恩度联合化疗可以改善和稳定晚期恶性肿瘤患者的生活质量,延长无疾病进展时间,其毒性低,安全性好,值得临床推广和进一步研究。

Objective To investigate the efficacy and safety of rh-endostatin injection（endostar） combinedwith chemotherapy on the advanced malignancies.Methods By histopathology or cytology confirmed IV patients with malignant tumor 18 cases,of which 10 cases of non-small cell lung cancer,gastrointestinal tumors 6 cases,other tumors in 2 cases.Endostar patients combined chemotherapy regimen,while the joint past of unused or past treatment of non-cross-resistance to chemotherapy drugs.21 days of a cycle.Evaluation of drug toxicity can be done affer a cycle,after two cycles evaluated efficacy.Results Among 18 cases,there were 10 cases achieved PR,4 cased of SD,and 4 cases of PD.The objective response rate（RR） was 55.6%（10/18）and disease control rate（DCR） was 77.78%（14/18）.Conclusion Endostar combined with chemotherapy can improve the quality of life in patients with advanced malignant tumors and prolong disease-free time to progression,its low toxicity,safety,good,worthy to be popularized and further study.